CNTX
Context Therapeutics Inc
NASDAQ · Pharmaceuticals
$2.28
+0.02 (+0.89%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.12M | 24.12M | 28.34M |
| Net Income | 5.84M | 5.30M | 5.57M |
| EPS | — | — | — |
| Profit Margin | 21.6% | 22.0% | 19.7% |
| Rev Growth | -4.2% | +22.6% | +13.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 115.33M | 93.38M | 118.18M |
| Total Equity | 83.91M | 94.52M | 81.63M |
| D/E Ratio | 1.37 | 0.99 | 1.45 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 7.13M | 6.78M | 8.30M |
| Free Cash Flow | 3.88M | 4.04M | 6.28M |